PMS2 alterations were present in 10 patients overall, most commonly in the STS cohort (n=6), including two patients with leiomyosarcoma, two patients with sarcoma NOS, and one patient each with myxofibrosarcoma and pleomorphic liposarcoma. This evidence concerns the gene PMS2 and sarcoma.